about
Positron emitting 18F-2-deoxy-2-fluoro-D-glucose: potential hot new therapyFrom bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Objective physical and mental markers of self-reported fatigue in women undergoing (neo)adjuvant chemotherapy for early-stage breast cancerIntracardiac metastasis of germ cell tumor complicated by pulmonary hypertension and thrombocytopenia.A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies.Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.Genomic mutation-driven metastatic breast cancer therapy: a single center experienceFunctional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.The effect of aromatase inhibition on the cognitive function of older patients with breast cancer.Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer.Barriers to treatment in patients with locally advanced breast cancerA phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety.Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy.Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional ageCognitive changes associated with endocrine therapy for breast cancer.Male breast cancer: an update in diagnosis, treatment and molecular profilingSecretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment.Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer.Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer.Inflammatory Biomarkers, Comorbidity, and Neurocognition in Women With Newly Diagnosed Breast CancerSERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.Tamoxifen, hot flashes and recurrence in breast cancer.Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistanceDietary pattern influences breast cancer prognosis in women without hot flashes: the women's healthy eating and living trialTriple-negative breast cancer: novel therapies and new directions.Adjuvant chemotherapy for older adults with breast cancer: making the standard a standard.Studying cancer-related fatigue: report of the NCCN scientific research committee.Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer.Assessment of knowledge about cancer pain management by physicians in training.Time to Treatment: Measuring Quality Breast Cancer Care.Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.Severe interstitial pneumonitis associated with docetaxel administration.An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy.The efficacy of breast MRI in predicting breast conservation therapy.Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy.Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer.Severe menopausal symptoms are widespread among survivors of breast cancer treatment regardless of time since diagnosis.
P50
Q24803118-4744E99F-2819-449F-9E3A-B396E30EA5F2Q28084982-B0A4C07C-FB09-4C31-9EB8-AD0B170E06FEQ30490643-4B829D00-1BA3-470E-8A8E-D7CC4FBB38FAQ33376190-2775D7AB-4998-4296-80C9-1736D66B2C14Q33427321-7B1AA16E-7E65-41EB-A6F5-23AB4F845338Q33440543-E9AF0D4B-1845-41DD-B612-28447E4B8CADQ33688687-15ED9799-57D8-4644-9E32-A91DD0BBC6A9Q33854382-E9EF2244-D264-471F-BFD1-2BD626D9AC0AQ33921226-79F4124F-089F-428F-8460-601441C3EF68Q34033757-A4787F19-B634-4495-B82D-EF0E56551A3BQ34156294-ED9E9894-5E8C-4EF9-A85E-2A840E250AC9Q34523934-41C023DE-7882-4C57-B8A8-71C1E1C1981AQ34567451-B448F675-7368-4144-AA4B-7A47638DD08AQ34687059-DBFBA1AB-D69C-4ADB-8A2F-E3E06F6CBA83Q34842494-62891438-F557-4F79-98AB-FC279332BE70Q34959972-FE1F13C2-5ED0-4537-9B1A-51CF0444CFE8Q35660927-4FD250B0-5C12-4EA0-8D74-CB9789A28944Q35660943-BCAD9D41-9194-4439-9EAE-3E0EC9743130Q35865088-DFE3FE92-CA9D-4E6D-8AA4-FC399BCF4F2FQ35933411-63FDDF5B-EEB5-4744-8238-3E6070AB2663Q36148915-85C1FA25-B3DA-405C-80AC-3FC251187E7DQ36173493-C2F52011-8466-4F59-B11F-2B5F36EEE226Q36413297-73242CB9-A268-459C-8BD6-4146FDE87634Q36614876-5EB5EFF2-1F09-4000-AE67-52F4FFB34E87Q36953961-68928392-2F97-427F-B611-61385052E50FQ37088657-3EB26905-BDFC-4166-825F-A3266F8F6DDAQ37104757-F0D3540F-CA66-4F02-A89B-2108E57C51A1Q37562457-2400A27A-D5BC-4D80-B7E7-0FCBBF93DED1Q37585297-E9AC33BC-2273-4322-85E6-59E893DFB2CFQ37819470-AD623A7D-6A6A-4C68-B199-FCFAD745A9DEQ38636006-C477E9A8-3642-4889-A11C-BD9BE1E2A4CBQ39454823-86EF0F88-C1AE-4E89-9114-5D10BAC705A9Q39509930-C687FE3C-8A1E-48E5-A0AD-1D4ED4898379Q39787293-AF43B24C-04AD-441C-83E9-D20418324590Q40588005-17717295-1F6E-4BF0-961F-787CB0C5D936Q41492616-8D6F17C5-0E14-417A-9430-3C8D1EE0592CQ43500077-4F8F7C61-22F5-4655-B05A-2E1338D773CBQ43943669-3B286F26-17F7-4685-9EA8-50E60727EB8CQ45817070-CD4176D6-C886-4C33-BEED-61F08D2D0DC5Q46106314-D84E18B1-7DE1-417C-94FC-09C002B04776
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joanne E Mortimer
@ast
Joanne E Mortimer
@en
Joanne E Mortimer
@es
Joanne E Mortimer
@nl
type
label
Joanne E Mortimer
@ast
Joanne E Mortimer
@en
Joanne E Mortimer
@es
Joanne E Mortimer
@nl
prefLabel
Joanne E Mortimer
@ast
Joanne E Mortimer
@en
Joanne E Mortimer
@es
Joanne E Mortimer
@nl
P108
P106
P1153
7102512809
P31
P496
0000-0002-2935-1934